Pharma BD Deal Intelligence
Synergies were captured and Sutent became a real oncology asset, but the deal is remembered mainly for the Bextra safety scandal, a $2.3B fraud settlement, and a decade of stagnant Pfizer R&D productivity and stock underperformance.
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Pfizer's $60 billion acquisition of Pharmacia would create a firm with 10% global market share and projected 2002 revenue of $48 billion, nearly double…
Pfizer and Pharmacia began operating as a unified company on April 16, 2003. The combined company had a 2003 R&D budget of $7.1 billion and treated nearly…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Announced July 2002, closed April 16, 2003. ~$60B stock-for-stock; FTC consent decree on close. Created #1 global drugmaker.
Synergies were captured and Sutent became a real oncology asset, but the deal is remembered mainly for the Bextra safety scandal, a $2.3B fraud settlement, and a decade of stagnant Pfizer R&D productivity and stock underperformance.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Pharmacia Corporation (this deal) | 2003 | $60.0B | 60 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2003 deals · Pfizer Inc. deals · Multiple (undisclosed) deals